Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company, will have its CEO, Richard Peters, present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company, will have its CEO, Richard Peters, present at the H.C. Wainwright BioConnect Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7 a.m. EST through the conference portal and Yumanity's website. The company is focused on developing therapies for neurodegenerative diseases, with its leading candidate, YTX-7739, in clinical trials for Parkinson’s disease.
Details
News Market Reaction – YMTX
The recorded move for YMTX in the trading session of this news was -9.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, being held virtually January 10-13, 2022.
The presentation will be available on-demand via the conference portal and through the Company's website at www.yumanity.com/events beginning at 7 a.m. EST, January 10.
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is in clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.
Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006
Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D.
rflamm@burnsmc.com
(212) 213-0006
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.